Literature DB >> 16362775

Effects of retigabine on the neurodegeneration and extracellular glutamate changes induced by 4-aminopyridine in rat hippocampus in vivo.

Gabriela Mora1, Ricardo Tapia.   

Abstract

We have previously shown that microdialysis perfusion of the K+ channel blocker 4-aminopyridine (4-AP) in rat hippocampus induces convulsions and neurodegeneration, due to the stimulation of glutamate release from synaptic terminals. Retigabine is an opener of the KCNQ2/Q3-type K+ channel that possesses antiepileptic action and may be neuroprotective, and we have therefore studied its effect on the hyperexcitation, the neuronal damage and the changes in extracellular glutamate induced by 4-AP. Retigabine and 4-AP were co-administered by microdialysis in the hippocampus of anesthetized rats, with simultaneous recording of the EEG, and the extracellular concentration of glutamate was measured in the microdialysis fractions. In 70-80% of the rats tested retigabine reduced the 4-AP-induced stimulation of glutamate release and prevented the neuronal damage observed at 24 h in the CA1 hippocampal region. However, retigabine did not block the EEG epileptic discharges and their duration was reduced in only 20-25% of the tested animals. We conclude that the neuroprotective action of retigabine is probably due to the blockade of the 4-AP-induced stimulation of glutamate release. This inhibition, however, was not sufficient to block the epileptic activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16362775     DOI: 10.1007/s11064-005-8834-8

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  51 in total

1.  KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel.

Authors:  H S Wang; Z Pan; W Shi; B S Brown; R S Wymore; I S Cohen; J E Dixon; D McKinnon
Journal:  Science       Date:  1998-12-04       Impact factor: 47.728

2.  A summary of the acute toxicity of 4-aminopyridine to birds and mammals.

Authors:  E W Schafer; R B Brunton; D J Cunningham
Journal:  Toxicol Appl Pharmacol       Date:  1973-12       Impact factor: 4.219

3.  A neurochemical study of the novel antiepileptic drug retigabine in mouse brain.

Authors:  G J Sills; C Rundfeldt; E Butler; G Forrest; G G Thompson; M J Brodie
Journal:  Pharmacol Res       Date:  2000-12       Impact factor: 7.658

4.  Influence of retigabine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 mice.

Authors:  G De Sarro; E D Di Paola; G Conte; M P Pasculli; A De Sarro
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2001-03       Impact factor: 3.000

5.  Delayed sclerosis, neuroprotection, and limbic epileptogenesis after status epilepticus in the rat.

Authors:  Ulrich Ebert; Claudia Brandt; Wolfgang Löscher
Journal:  Epilepsia       Date:  2002       Impact factor: 5.864

6.  Seizures and wet-dog shakes induced by 4-aminopyridine, and their potentiation by nifedipine.

Authors:  J Fragoso-Veloz; L Massieu; R Alvarado; R Tapia
Journal:  Eur J Pharmacol       Date:  1990-03-27       Impact factor: 4.432

7.  Poisoning with 4-aminopyridine: report of three cases.

Authors:  D A Spyker; C Lynch; J Shabanowitz; J A Sinn
Journal:  Clin Toxicol       Date:  1980-06       Impact factor: 4.467

8.  D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures.

Authors:  A Rostock; C Tober; C Rundfeldt; R Bartsch; J Engel; E E Polymeropoulos; B Kutscher; W Löscher; D Hönack; H S White; H H Wolf
Journal:  Epilepsy Res       Date:  1996-04       Impact factor: 3.045

Review 9.  Potassium channels as anti-epileptic drug targets.

Authors:  Alan D Wickenden
Journal:  Neuropharmacology       Date:  2002-12       Impact factor: 5.250

10.  M channels containing KCNQ2 subunits modulate norepinephrine, aspartate, and GABA release from hippocampal nerve terminals.

Authors:  Maria Martire; Pasqualina Castaldo; Monia D'Amico; Paolo Preziosi; Lucio Annunziato; Maurizio Taglialatela
Journal:  J Neurosci       Date:  2004-01-21       Impact factor: 6.167

View more
  6 in total

1.  Retigabine: has the orphan found a home?

Authors:  Elinor Ben-Menachem
Journal:  Epilepsy Curr       Date:  2007 Nov-Dec       Impact factor: 7.500

2.  Retigabine: in partial seizures.

Authors:  Greg L Plosker; Lesley J Scott
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

3.  Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model.

Authors:  Jarogniew J Luszczki; Jim Z Wu; Grzegorz Raszewski; Stanislaw J Czuczwar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-09-05       Impact factor: 3.000

4.  Effects of Levetiracetam, Carbamazepine, Phenytoin, Valproate, Lamotrigine, Oxcarbazepine, Topiramate, Vinpocetine and Sertraline on Presynaptic Hippocampal Na(+) and Ca(2+) Channels Permeability.

Authors:  María Sitges; Luz María Chiu; Ronald C Reed
Journal:  Neurochem Res       Date:  2015-11-05       Impact factor: 3.996

5.  Effect of the Anti-depressant Sertraline, the Novel Anti-seizure Drug Vinpocetine and Several Conventional Antiepileptic Drugs on the Epileptiform EEG Activity Induced by 4-Aminopyridine.

Authors:  Maria Sitges; Blanca Irene Aldana; Ronald Charles Reed
Journal:  Neurochem Res       Date:  2016-01-30       Impact factor: 3.996

6.  Beneficial effect of retigabine on memory in rats receiving ethanol.

Authors:  Ewa Zwierzyńska; Agata Krupa-Burtnik; Bogusława Pietrzak
Journal:  Pharmacol Rep       Date:  2020-12-31       Impact factor: 3.024

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.